Beijing Beilu Pharmaceutical (SHE:300016) — Market Cap & Net Worth
Market Cap & Net Worth: Beijing Beilu Pharmaceutical (300016)
Beijing Beilu Pharmaceutical (SHE:300016) has a market capitalization of $780.01 Million (CN¥5.33 Billion) as of May 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #10279 globally and #2966 in its home market, demonstrating a -3.37% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Beijing Beilu Pharmaceutical's stock price CN¥9.47 by its total outstanding shares 562873163 (562.87 Million). Analyse 300016 cash generation efficiency to see how efficiently the company converts income to cash.
Beijing Beilu Pharmaceutical Market Cap History: 2015 to 2026
Beijing Beilu Pharmaceutical's market capitalization history from 2015 to 2026. Data shows change from $1.86 Billion to $780.01 Million (-6.34% CAGR).
Beijing Beilu Pharmaceutical Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Beijing Beilu Pharmaceutical's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.52x
Beijing Beilu Pharmaceutical's market cap is 0.52 times its annual revenue
Latest Price to Earnings (P/E) Ratio
37.41x
Beijing Beilu Pharmaceutical's market cap is 37.41 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.86 Billion | $491.43 Million | $32.58 Million | 3.78x | 57.02x |
| 2016 | $967.05 Million | $498.86 Million | $16.38 Million | 1.94x | 59.04x |
| 2017 | $717.22 Million | $522.54 Million | $118.82 Million | 1.37x | 6.04x |
| 2018 | $551.66 Million | $608.05 Million | $147.76 Million | 0.91x | 3.73x |
| 2019 | $715.26 Million | $819.12 Million | $342.44 Million | 0.87x | 2.09x |
| 2020 | $765.66 Million | $827.34 Million | $174.70 Million | 0.93x | 4.38x |
| 2021 | $740.16 Million | $843.90 Million | $125.51 Million | 0.88x | 5.90x |
| 2022 | $531.44 Million | $765.88 Million | $11.28 Million | 0.69x | 47.10x |
| 2023 | $586.45 Million | $890.72 Million | -$71.76 Million | 0.66x | N/A |
| 2024 | $510.67 Million | $983.55 Million | $13.65 Million | 0.52x | 37.41x |
Competitor Companies of 300016 by Market Capitalization
Companies near Beijing Beilu Pharmaceutical in the global market cap rankings as of May 4, 2026.
Key companies related to Beijing Beilu Pharmaceutical by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.15 |
Beijing Beilu Pharmaceutical Historical Marketcap From 2015 to 2026
Between 2015 and today, Beijing Beilu Pharmaceutical's market cap moved from $1.86 Billion to $ 780.01 Million, with a yearly change of -6.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥780.01 Million | +19.27% |
| 2025 | CN¥653.99 Million | +28.06% |
| 2024 | CN¥510.67 Million | -12.92% |
| 2023 | CN¥586.45 Million | +10.35% |
| 2022 | CN¥531.44 Million | -28.20% |
| 2021 | CN¥740.16 Million | -3.33% |
| 2020 | CN¥765.66 Million | +7.05% |
| 2019 | CN¥715.26 Million | +29.65% |
| 2018 | CN¥551.66 Million | -23.08% |
| 2017 | CN¥717.22 Million | -25.83% |
| 2016 | CN¥967.05 Million | -47.94% |
| 2015 | CN¥1.86 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Beijing Beilu Pharmaceutical was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $780.01 Million USD |
| MoneyControl | $780.01 Million USD |
| MarketWatch | $780.01 Million USD |
| marketcap.company | $780.01 Million USD |
| Reuters | $780.01 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Beijing Beilu Pharmaceutical
Beijing Beilu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. The company provides contrast agents, such as gadopentetate meglumine injection, gadobutrol injection, and gadobenate meglumine injection for MRI contrast; and iohexol injection, iopamidol injection, and iodixanol injection for CT contrast, as well as glimepiride … Read more